Twiggy's Invex Therapeutics | The Imminent Coin Flip, page-168

I'll chime in. Current issue is a large seller desperate to get out before EOFY with an illiquid stock which is why we are at a zero EV. Well into phase 3, tbh we should be at least $2. Besides the run up to trial ending/readout (which should begin this time next year), the only other short term catalyst is a second indication which was hinted to at their last 4C. That could be anything from stroke to brain injuries. Trial recruitment is also humming along. Other than the BoD not buying on market at these prices they have not put a foot wrong (which is rare for the ASX). For some strange reason, I still get the feeling a buyout could be on the cards before the trial ends but that's just a gut feel.